Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Identifying a biomarker for Alzheimer's disease that can be obtained from a blood sample has been a goal of researchers for many years. Over the past few years a number of investigators have studied several plasma biomarkers but most frequently plasma amyloid Aβ40 and Aβ42 while others have explored the use of genetic variants as biomarkers for diagnosis or risk. This review considers the cross sectional and longitudinal data regarding plasma Aβ40 and Aβ42 as diagnostic biomarkers as well as risk biomarkers. Review of recent genome wide association studies indicates as many as 10 genetic variants have been associated with susceptibility to AD. Further analysis suggests that these factors have modest effects on risk and are thus not helpful, as yet in the diagnosis of disease. Until the function of these genes is understood, their role in risk and diagnosis will remain uncertain. Thus, there are several types of peripheral biomarkers under investigation, but more work is required before that can be deemed clinically useful.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Self-citationHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
CSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 2×
“In the CSF, low levels of Aβ42 and Aβ42/Aβ40 ratios in patients with MCI are associated with higher brain amyloid load(Fagan, Mintun et al. 2006; Fagan, Roe et al. 2007)and predict conversion to LOAD(Blennow and Hampel 2003; Blennow and Vanmechelen 2003; Hansson, Zetterberg et al. 2006).”
BackgroundInverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ 42 in humans
Fagan, A. M., Mintun, M. A., Mach, R. H., Lee, S., Dence, C. S., Shah, A. R., LaRossa, G. N., Spinner, M. L., Klunk, W. E., Mathis, C. A., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20730 · Cited by 1,246
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Cited by
The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Liu, E., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.05.1769 · Cited by 1,010
Ovod, V., Ramsey, K. N., Mawuenyega, K. G., Bollinger, J. G., Hicks, T., Schneider, T., Sullivan, M., Paumier, K., Holtzman, D. M., Morris, J. C., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.06.2266 · Cited by 585
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.11.001 · Cited by 348
The future of blood‐based biomarkers for Alzheimer's disease
Henriksen, K., O'Bryant, S. E., Hampel, H., Trojanowski, J. Q., Montine, T. J., Jeromin, A., Blennow, K., Lönneborg, A., Wyss‐Coray, T., Soares, H., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.01.013 · Cited by 313
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Serum Exosomal miR-223 Serves as a Potential Diagnostic and Prognostic Biomarker for Dementia
Wei, H., Xu, Y., Xu, W., Zhou, Q., Chen, Q., Yang, M., Feng, F., Liu, Y., Zhu, X., Yu, M., et al. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.03.016 · Cited by 84
Amyloid Hypothesis: Is There a Role for Antiamyloid Treatment in Late-Life Depression?
Mahgoub, N., & Alexopoulos, G. S. (2016) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2015.12.003 · Cited by 81
“Aβ findings are complex and may include methodological differences across studies and the effect of disease stage on Aβ levels possibly reflecting sequestration of Aβ42 in senile plaques or semi-soluble oligomers (32).”
Yao, F., Hong, X., Li, S., Zhang, Y., Zhao, Q., Du, W., Wang, Y., & Ni, J. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180261 · Cited by 52
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
Kim, H. J., Park, K. W., Kim, T. E., Im, J. Y., Shin, H. S., Kim, S., Lee, D. H., Ye, B. S., Kim, J. H., Kim, E.-J., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143018 · Cited by 42
Dynamic Blood Concentrations of Aβ1–40 and Aβ1–42 in Alzheimer’s Disease
Yang, Y.-H., Huang, L.-C., Hsieh, S.-W., & Huang, L.-J. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00768 · Cited by 39
Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease
Sutphen, C. L., Fagan, A. M., & Holtzman, D. M. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.07.031 · Cited by 31
Differential processing of amyloid precursor protein in brain and in peripheral blood leukocytes
Delvaux, E., Bentley, K., Stubbs, V., Sabbagh, M., & Coleman, P. D. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.004 · Cited by 26
“…it has been shown that leukocytes express APP (e.g. Konig et al., 1992; Li et al., 1999) and that peptides produced from APP may serve as AD biomarkers (e.g. Holtzman, 2011; Mayeux and Schupf, 2011), we hypothesized that APP processing in leukocytes may be similar to APP processing in the brain.”
BackgroundPlasma biomarkers are associated with agitation and regional brain atrophy in Alzheimer’s disease
Hsu, J.-L., Lee, W.-J., Liao, Y.-C., Lirng, J.-F., Wang, S.-J., & Fuh, J.-L. (2017) · Scientific Reports · doi:10.1038/s41598-017-05390-1 · Cited by 18
Metadata
- Authors
- Mayeux, R., & Schupf, N.
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 2011-12
- Volume
- 32
- Pages
- S10-S19
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W1989913005
- Cited by
- 79
- References
- 25
- FWCI
- 4.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.